ABCL - AbCellera partnering with Atlas Ventures on development of therapeutic antibodies
- AbCellera Biologics ( NASDAQ: ABCL ) has entered into a partnership with Atlas Ventures to discover therapeutic antibodies for up to three drug targets .
- Terms call for Atlas to have the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera ( ABCL ) will receive research payments and is eligible for milestone payments and royalties on sales of products.
- AbCellera's ( ABCL ) technology is based on its Trianni transgenic mouse platform. Atlas is a biotech venture capital firm.
- Seeking Alpha's Quant Rating views AbCellera ( ABCL ) as a hold with high marks for profitability, momentum, and revisions .
For further details see:
AbCellera partnering with Atlas Ventures on development of therapeutic antibodies